Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
about
A review on the strategies for oral delivery of proteins and peptides and their clinical perspectivesAmphiphilic cholic-acid-modified dextran sulfate and its application for the controlled delivery of superoxide dismutase.Lessons learned from the clinical development of oral peptides.Oral calcitonin.Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trialThe future of osteoarthritis therapeutics: emerging biological therapy.Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options.Individualizing osteoporosis therapy.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.The oral delivery of peptides and proteins: established versus recently patented approaches.Salmon calcitonin use and associated cancer risk.The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?Formulation strategies to improve oral peptide delivery.Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primerChallenges in oral peptide delivery: lessons learnt from the clinic and future prospects.Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.
P2860
Q26744008-88B4AB55-8DD4-4BC1-B5DC-21166F8EC667Q34274061-ADFC3C0D-DD2C-426D-A9A7-D1C30B329E0FQ35557405-12DF3055-4816-450C-894E-738CBF46A098Q36311630-E5CB77CE-2A34-4A58-B5DA-A895B0890A1CQ36471074-466DE014-6129-4794-AA23-B00E92659D58Q37333939-1F3C15AC-28A8-4B08-9612-E762013D0D41Q37951107-8C310863-9D45-4EBE-BE0A-465FD12C5996Q37973239-FEB93136-7CD4-4CA9-A2B3-013E04BA22CEQ38110433-59BBC447-F57D-415D-AF9E-3DD52A42871FQ38162959-9710556C-FDF8-46D0-B27B-2D01DB555390Q38164665-5900F9DB-E86C-4B2D-B535-E201892DDF80Q38166991-ECF5A80B-D701-4A99-9BA2-6569F6DA036FQ38226675-7E863B67-47BC-4CCD-8D24-EB41CCF7BABBQ38268308-32CD75F0-5823-4FF5-A184-2588A6FBD5BDQ38653884-7676F23A-574D-4BF2-970F-F845ED61E8E0Q38806177-C224C283-1E0A-4990-A216-F414C4F192BAQ42601360-B6F80981-B9BF-4620-B109-B6E016F4C700Q47371506-C9D7DF2A-CFE1-43BF-BD35-AE6A275CB55AQ47374720-4E146E23-030D-4BAE-B8AD-B9B07525DD20Q47590580-D8097EAB-C963-4D3A-813B-A924374C9929
P2860
Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lessons learned from the devel ...... in phase III clinical trials.
@en
Lessons learned from the devel ...... in phase III clinical trials.
@nl
type
label
Lessons learned from the devel ...... in phase III clinical trials.
@en
Lessons learned from the devel ...... in phase III clinical trials.
@nl
prefLabel
Lessons learned from the devel ...... in phase III clinical trials.
@en
Lessons learned from the devel ...... in phase III clinical trials.
@nl
P2093
P2860
P356
P1476
Lessons learned from the devel ...... in phase III clinical trials.
@en
P2093
A C Bay-Jensen
C Christiansen
I Byrjalsen
K Henriksen
M A Karsdal
P2860
P304
P356
10.1177/0091270010372625
P577
2010-07-21T00:00:00Z